Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AML Patients at Risk for Delayed Bone Marrow Recovery

J Clin Oncol; ePub 2016 Jun 27; Gerbing, et al

Publish date:: July 6, 2016

Telomere content at end of acute myeloid leukemia (AML) induction may identify those at highest risk for markedly delayed bone marrow recovery after therapy, according to a study involving 115 individuals.

Participants included those with (n=53) and without (n=62) significantly delayed neutrophil recovery after chemotherapy for AML. Investigators measured telomere content using quantitative polymerase chain reaction from remission bone marrow samples. Among the results:

• Less telomere content was significantly linked with prolonged neutropenia after the fourth and fifth chemotherapy courses.

• After adjusting for age, telomere content still independently predicted time to recovery of absolute neutrophil count for both courses.

• DNA analysis for germline mutations revealed no enrichment of rare or novel variants in the delayed recovery group.

Citation: Gerbing R, Alonzo T, Sung L, et al. Shorter remission telomere length predicts delayed neutrophil recovery after acute myeloid leukemia therapy: A report from the Children’s Oncology Group. [Published online ahead of print June 27, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.66.9622.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,